Author:
Breckenridge Alasdair,Liberti Lawrence
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Reference5 articles.
1. Liberti, L. et al. Adaptive licensing and facilitated regulatory pathways: a survey of stakeholder perceptions. Clin. Pharmacol. Ther. 98, 477–479 (2015).
2. Bujar, M., McAuslane, N. M. & Liberti, L. New drug approvals in ICH countries 2007–2016. CIRS April 2017.
3. Woloshin, S., Schwartz, L. M., White, B. & Moore, T. J. The fate of FDA postapproval studies. N. Engl. J. Med. 377, 1114–1117 (2017).
4. Food and Drug Administration. Report on the performance of firms in conducting post marketing requirements and commitments. Fed. Regist. 81, 75411–75419 (2016).
5. Gellad, W. F. & Kesselheim, A. S. Accelerated approval and expensive drugs. N. Engl. J. Med. 376, 2001–2004 (2017).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献